Study S001605

A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease

ClinicalTrials.gov record

Registration

Registration: NCT05882045
Acronym: TRIUMPH-3
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 1946
Start: 2023-05-30
Primary completion: 2026-04-16
Lead sponsor: Eli Lilly and Company
Conditions: Obesity; Cardiovascular Diseases
Interventions: DRUG:Retatrutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:J1I-MC-GZBM; OTHER:2023-503659-88-00; NIH:2023

Registered primary outcomes

Percent Change from Baseline in Body Weight [Baseline, Week 80]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.